1. Home
  2. Cdk4 Inhibitor

Contact Angene

Tel: +852 8191 6999

Email: [email protected]

Brc1cnc(nc1)C
Pyrimidine, 5-bromo-2-methyl-
CCCP1(=O)OP(=O)(CCC)OP(=O)(O1)CCC
1,3,5,2,4,6-Trioxatriphosphorinane, 2,4,6-tripropyl-, 2,4,6-trioxide
CC1(C)OB(OC1(C)C)B1OC(C(O1)(C)C)(C)C
2,2'-Bi-1,3,2-dioxaborolane, 4,4,4',4',5,5,5',5'-octamethyl-
O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.[Pd].[Pd]
Tris(dibenzylideneacetone)dipalladium
C1CCC(CC1)P(C1CCCCC1)C1CCCCC1.Cc1cc(C)c(c(c1)C)N1CCN(C1=[Ru](=Cc1ccccc1)(Cl)Cl)c1c(C)cc(cc1C)C
Ruthenium,[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)-, (SP-5-41)-

Cdk4 Inhibitor

Brc1ccc2c(c1)[nH]c1c2c2c(=O)[nH]c(=O)c2c2c1[nH]c1c2cccc1 Request for Quotation
Chemical Name: Cdk4 Inhibitor
CAS Number: 546102-60-7
Product Number: AG01E4PH(AGN-PC-0LQ50A)
Synonyms:
MDL No:
Molecular Formula: C20H10BrN3O2
Molecular Weight: 404.2163

Identification/Properties

Computed Properties
Molecular Weight:
404.223g/mol
XLogP3:
4.3
Hydrogen Bond Donor Count:
3
Hydrogen Bond Acceptor Count:
2
Rotatable Bond Count:
0
Exact Mass:
402.996g/mol
Monoisotopic Mass:
402.996g/mol
Topological Polar Surface Area:
77.8A^2
Heavy Atom Count:
26
Formal Charge:
0
Complexity:
657
Isotope Atom Count:
0
Defined Atom Stereocenter Count:
0
Undefined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Covalently-Bonded Unit Count:
1
Compound Is Canonicalized:
Yes

Safety Information

NMR Spectrum

Other Analytical Data

Request for Quotation

Customer Feedback

Chemical Structure


The cyclin-dependent kinase 4 (Cdk4) inhibitor is a vital component in chemical synthesis processes, particularly in the realm of drug development and medicinal chemistry. Through its role in blocking the activity of Cdk4, this inhibitor exerts a significant influence on cell cycle progression and proliferation. In chemical synthesis, the selective inhibition of Cdk4 can be harnessed to control the production of specific molecules and compounds, allowing for more precise and targeted synthesis pathways. By incorporating Cdk4 inhibitors into synthetic protocols, chemists can achieve greater control over the reactions involved, resulting in the efficient creation of complex molecules with potential pharmaceutical applications.